Bile duct cancer
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Where to go
4 hospitals in India taking patients for this trial.
Registry summary (technical)
The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer.
Sponsor: Jazz Pharmaceuticals
NCT06282575 on ClinicalTrials.gov
Last updated on the registry 14 Sep 2026 · read by us 20 Oct 2026